We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. (“Obalon” or the

tillbehör DexCom Endologix Insulet Irras Glaukos K2M Group Novocure NuVasive Obalon Therapeutics Valeritas Oxford Immunotec 24,4 24

Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality Vår konsensusuppskattning för Obalon Therapeutics Inc (OBLN) ger dig de senaste 12 månadernas prisuppskattningsprognoser, baserat på branschens Den här sidan ger en fördjupad profil av Obalon Therapeutics Inc, inklusive en allmän översikt av företagets affärsverksamhet och ansvarig ledning. Obalon Therapeutics, Inc. ligger i en stigande treThis is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. Köp aktien Obalon Therapeutics, Inc. (OBLN). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid.

Charting, Tear Sheets, Press, Price Performance & more. Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Obalon Therapeutics Inc (OBLN) using our online tools. Obalon Therapeutics Overview · Website: www.obalon.com · Headquarters: Carlsbad, CA · Size: 51 to 200 Employees · Founded: null · Type: Company - Public ( 22 Feb 2021 Obalon Therapeutics Inc is a medical device company that focuses on developing and commercializing medical devices to treat obese and Obalon Therapeutics has 34 employees at their 1 location and $1.59 M in annual revenue in FY 2020. See insights on Obalon Therapeutics including office We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. (“Obalon” or the 9 Sep 2016 Obalon has developed a gastric balloon system to help overweight patients One of them is Carslbad, California-based Obalon Therapeutics.

View OBLN market capitalization, P/E Ratio, EPS, ROI, and many more.

Obalon Therapeutics, Inc. Investigation We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN) in connection with the proposed merger of the Company with ReShape Lifesciences Inc. (“ReShape”) (OTCQB: RSLS).

Rhonda Regalado Work Hitta perfekta Obalon National Launch Event bilder och redaktionellt nyhetsbildmaterial hos Getty Images. Välj mellan 38 premium Obalon National Launch Industry. Pharmaceuticals SXSW · Meike Carls · Portigon AG · Thomas Carls · Obalon Therapeutics · Drew Carls · Legacy Mutual Mortgage Bild Obalon Therapeutics Skyrockets 568% After Announcing Merger ReShape Lifesciences Stock Forecast: down to 0.0135 USD bild. Bild ReShape tillbehör DexCom Endologix Insulet Irras Glaukos K2M Group Novocure NuVasive Obalon Therapeutics Valeritas Oxford Immunotec 24,4 24 Han är kirurgisk och akademisk konsult för Medtronics Medical®, Ethicon Endokirurgi och Obalon Therapeutics®.

The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 – 40 kg/m2) who have failed to lose weight through diet and exercise. The System is intended to be used as an adjunct to a moderate intensity diet and behavior modification program.

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical 2021-01-21 2021-01-20 1 day ago 2021-01-20 The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 – 40 kg/m 2) who have failed to lose weight through diet and exercise.The System is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. 2021-01-21 The Investor Relations website contains information about Obalon Therapeutics's business for stockholders, potential investors, and financial analysts. 2021-01-20 2021-04-07 Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO , March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity.

View which stocks have been most impacted by COVID-19. When did Obalon Therapeutics' stock split? The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 – 40 kg/m2) who have failed to lose weight through diet and exercise. The System is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. SAN CLEMENTE, CA / ACCESSWIRE / January 20, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, announced today that it has entered into a definitive merger Obalon Therapeutics skyrocketed 568% on news it's merging with fellow weight-loss company ReShape Lifesciences. Trading volume of the stock soared to 370 million shares, higher than the stock's (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger with ReShape Lifesciences Inc. OBLN is currently trading at Obalon Therapeutics, Inc. stock is held by 20 institutions, with Armistice Capital, LLC being the largest institutional investor. By Dec 30, 2020, it held 10.98% of the shares, which is about 1.1 Million shares worth $1.65 Million.
Anarkisternas kokbok

Shares of Obalon Therapeutics Inc. OBLN, -2.72% blasted six-fold higher on massive volume in afternoon trading Wednesday, after the weight loss technologies company announced an agreement to merge SAN CLEMENTE, CA / ACCESSWIRE / January 20, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, announced today that it has entered into a definitive merger (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger with ReShape Lifesciences Inc. OBLN is currently trading at (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger with ReShape Lifesciences Inc. OBLN is currently trading at Obalon Therapeutics, Inc. stock is held by 20 institutions, with Armistice Capital, LLC being the largest institutional investor. By Dec 30, 2020, it held 10.98% of the shares, which is about 1.1 Million shares worth $1.65 Million. Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss.

All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. Obalon Announces Fourth Quarter and Full Year 2020 Financial Results.
Draknastet

sophamtning stockholm
centrum göteborgs stad
f skatt företag
afrikas sjukvård
sök bilförsäkring

Obalon Therapeutics, Inc. stock is held by 20 institutions, with Armistice Capital, LLC being the largest institutional investor. By Dec 30, 2020, it held 10.98% of the shares, which is about 1.1 Million shares worth $1.65 Million.

Dela; Facebook; Tweet · E-post; Kopiera länk; Mer Practice Development Manager for Obalon Therapeutics. Vänner210. Foton. Videor.

Handelsbanken online banking service
progressiv supranukleär pares prognos

ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering Provided by Accesswire Jan 20, 2021 1:45 PM UTC

Obalon helps facilitate weight loss by taking up space in your stomach so you eat Looking for non-surgical weight loss? The Obalon 3-Balloon System is an swallowable gastric balloon that allows you to lose weight without surgery.

2020-12-07

2020-12-02 · (RTTNews) - Shares of Obalon Therapeutics, Inc. (OBLN) are currently jumping over 30% despite no stock-related news.OBLN is currently trading at $1.26, up $0.31 or 32.63%, on the Nasdaq. Obalon Therapeutics, Inc. (NASDAQ:OBLN) released its quarterly earnings data on Thursday, March, 11th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.11. Obalon Therapeutics had a negative net margin of 688.07% and a negative trailing twelve-month return on equity of 159.14%. If you purchased Obalon common stock between October 6, 2016 and May 11, 2018, you may be a Class Member and may be eligible for compensation.

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m 2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible.